SIPPET: Pre-and Post-Study Hemophilia Meeting


Active Substance



Organized by Er-Kim İlaç A.Ş., the series of meeting named “SIPPET: Pre-and Post-Study Hemophilia” was performed successfully on February 19, 2015 in İzmir Key Hotel under the presidency of Prof. Dr. Kaan Kavaklı, lecturer in Ege University and Prof. Dr. Bülent Zülfikar lecturer in İstanbul University, with broad participation of pediatric hematologists.

The meeting, in which the long-awaited SIPPET (Survey of Inhibitors in Plasma Product Exposed Toddlers) study comparing plasma derivative factor VIII (pdFVIII) products with recombinant factor VIII (rFVIII) preparations was discussed in depth, took place in two parts as Pre-SIPPET Study Hemophilia Treatment and Post-SIPPET Study Hemophilia Treatment.

Following the opening in which Prof. Dr. Bülent Zülfikar presented Turkey demographic data in the field of hemophilia, debater physicians found the opportunity to review the approaches physicians in different countries and related specialty associations to hemophilia care under also the direction of Prof. Dr. Bülent Zülfikar.

In the session in which Dr. Özlem Tüfekçi shared the Italian guidelines, Dr. Barış Malbora British guidelines and Dr. Yılmaz Ay French guidelines, the debaters expressed that all existing guidelines had been prepared before the SIPPET Study and shared the issue of the need of update of all country guidelines following the results of the SIPPET Study.

In the second part of the meeting, up-to-date information about the SIPPET Study, the preliminary results of which were explained by Dr. Peyvandi in the annual congress of the American Society of Hematology performed in December 2015 and then in the annual congress of European Association for Hemophilia and Allied Disorders (EAHAD), was presented by Dr. Kaan Kavaklı.

The issues such as if the hemophilia treatment would change after SIPPET and if so what would change, what would have to be done, what were the difficulties that would be faced, method to be followed, and the course of actions that would be taken by specialty associations and associations working groups were thoroughly discussed.

Stating that this meeting that was performed in the field of hemophilia was highly important regarding that it set the ground for the discussion of updated scientific information, the participants expressed the necessity of the attempts led by the specialty associations based on the inhibitor development, the most important issue of hemophilia.

SIPPET – Survey of Inhibitors in Plasma Product Exposed Toddlers

In this study, severe hemophilia patients who had not previously been treated with factor III (PUPs: Previously Untreated Patients) were included. According to the results obtained from the SIPPET Study in which the risk of inhibit development, currently the most critical issue in hemophilia treatment, was evaluated, more inhibitor development was reported to be seen in rFVIII than those of pdFVII originated.

SIPPETSurvey of Inhibitors in Plasma Product Exposed Toddlers
– 5 continents
– 14 countries
– 42 centers
– 3 centers from Turkey
– İstanbul – Prof. Dr. Bülent Zülfikar
– İzmir – Prof. Dr. Kaan Kavaklı
– Adana – Prof. Dr. Bülent Antmen
– 303 PUPs participated in the study.
– The first randomized, controlled, prospective clinical trial